Entera Bio Ltd. Ordinary Shares
Symbol: ENTX (NASDAQ)
1.87
▼ (-2.60%) -0.050
Company Description:
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Key Stats
- Today's Open: $1.9
- Today's High: $1.93
- Today's Low: $1.87
- Today's Volume: 34.86K
- Yesterday Close: $1.92
- Yesterday High: $1.98
- Yesterday Low: $1.86
- Yesterday Volume: 31.03K
- Last Min Volume: 2.94K
- Last Min High: $1.87
- Last Min Low: $1.87
- Last Min VWAP: $1.87
Company Profile
- Name: Entera Bio Ltd. Ordinary Shares
- Website: https://www.enterabio.com
- Listed Date: 2018-06-28
- Location: JERUSALEM, L3
- Market Status: Active
- CIK Number: 0001638097
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $87.67M
- Round Lot: 100
- Outstanding Shares: 45.66M
- Asset Type: CS
RECENT FILINGS FOR ENTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-08 | 10-Q | View |
| 2025-08-08 | 8-K | View |
| 2025-07-28 | 8-K | View |
| 2025-07-18 | 4 | View |
| 2025-07-18 | 4 | View |
| 2025-07-18 | 4 | View |
| 2025-07-18 | 8-K | View |
| 2025-06-06 | EFFECT | View |
| 2025-06-06 | 424B3 | View |
| 2025-06-05 | DEFA14A | View |
| 2025-06-05 | ARS | View |
| 2025-06-05 | DEF 14A | View |
| 2025-06-04 | CORRESP | View |
| 2025-06-04 | UPLOAD | View |
| 2025-05-30 | S-8 | View |
| 2025-05-30 | S-3 | View |
| 2025-05-23 | UPLOAD | View |
| 2025-05-20 | 3 | View |
| 2025-05-20 | CORRESP | View |
| 2025-05-14 | PRE 14A | View |
Latest News on ENTX